Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason

ObjectiveBiosimilars represent a new opportunity for inflammatory bowel disease (IBD) treatment and economic sustainability of therapies. This study aimed to evaluate the efficacy and long-term safety of the adalimumab biosimilar ABP 501 in biologic-naïve vs. biologic-switched IBD patients.MethodsA...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Giammarco Mocci, Arianna Cingolani, Giorgia Orrù, Carla Felice, Francesca Maria Onidi, Gianmarco Lombardi, Davide Checchin, Raffaele Colucci, Laurino Grossi, Antonio Ferronato, Chiara Rocchi, Marta Ascolani, Paolo Usai Satta, Lucia Fanini, Stefano Pilati, Antonio Tursi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-10-01
Colecção:	Frontiers in Gastroenterology
Assuntos:	adalimumab ABP 501 biosimilar Crohn’s disease ulcerative colitis
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fgstr.2023.1218228/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!